What does ACADIA Pharmaceuticals do?

ACADIA Pharmaceuticals develops and sells medicines for brain-related and rare diseases. Its two marketed drugs are NUPLAZID, which treats hallucinations and delusions in people with Parkinson's disease, and DAYBUE, which treats symptoms of Rett syndrome, a rare neurodevelopmental disorder. It also has several experimental drugs in clinical trials for conditions such as Alzheimer's-related psychosis, depression, and tremor.

What is ACADIA Pharmaceuticals's fair value?

On an owner-earnings DCF, ACADIA Pharmaceuticals's most-likely fair value is about $34, versus a recent price near $20. A margin-of-safety estimate, not a price target. Analysis, not advice.

Healthcare · Biotechnology · ACAD

What ACADIA Pharmaceuticals Does & How It Makes Money (ACAD)

Updated October 2026 · reflects ACADIA Pharmaceuticals's latest reported financials

San Diego biotech selling medicines for Parkinson's psychosis and Rett syndrome. ACADIA earns revenue mainly from sales of its two approved drugs, NUPLAZID and DAYBUE, in North America.

ACADIA Pharmaceuticals's story, moat and numbers — in a 3-minute visual book.

Explore ACADIA Pharmaceuticals on TacticScale →

How ACADIA Pharmaceuticals makes money

ACADIA earns revenue mainly from sales of its two approved drugs, NUPLAZID and DAYBUE, in North America. It puts that money into clinical-stage programs, some developed through licensing and collaboration deals with partners such as Neuren and Stoke Therapeutics.

What ACADIA Pharmaceuticals does

ACADIA Pharmaceuticals is a San Diego-based biopharmaceutical company that focuses on neurological and rare diseases in North America. It has two commercial products. NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist, treats hallucinations and delusions associated with Parkinson's disease psychosis. DAYBUE, a synthetic analog of an IGF-1-derived tripeptide licensed from Neuren Pharmaceuticals, treats symptoms of Rett syndrome. Its pipeline includes remlifanserin (Phase 2, Alzheimer's disease psychosis and Lewy body dementia psychosis) and ACP-211 (Phase 2, major depressive disorder). Phase 1 programs are ACP-711 (essential tremor), ACP-271 (tardive dyskinesia and Huntington's disease), and ACP-2591 (Rett and fragile X syndromes). A discovery-stage RNA-based program for SYNGAP1 syndrome is run with Stoke Therapeutics. The company was founded in 1993 as Receptor Technologies and took the ACADIA name in 1997.

Products & services

NUPLAZID (pimavanserin)
DAYBUE (trofinetide)
remlifanserin
ACP-211
ACP-711
ACP-2591

What is ACADIA Pharmaceuticals worth?

On an owner-earnings DCF, ACADIA Pharmaceuticals's most-likely value is about $34 versus a recent price near $20 (73% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$13) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.

Verdict: Fairly priced — no edge

Owner-earnings fair value · recent price ≈ $20

Fair value (most likely)

$34

Range

$20–$72

No-growth floor

$13

Price

~$20

Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.

Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →

Sector Healthcare Industry Biotechnology HQ United States Ticker ACAD Official site

Related companies

Acadia Healthcare (ACHC) · Neurocrine Biosciences (NBIX) · Supernus Pharmaceuticals (SUPN) · PTC Therapeutics (PTCT) · Biogen (BIIB)

Understand ACADIA Pharmaceuticals in 3 minutes →